Top Ten 2024: Drug Pricing—340B Developments to Watch

Based on AHLA’s annual Health Law Connections article, this special series brings together thought leaders from across the health law field to discuss the top ten issues of 2024. In the tenth episode, Sarah Bowman, Principal, PYA, speaks with Jolee H. Bollinger, Deputy General Counsel, Sharp HealthCare, and Andrew D. Ruskin, Partner, K&L Gates LLP, about potential 340B activity in 2024 as drug manufacturers continue to tighten access to 340B pricing. They discuss the impact of the Genesis case, how covered entities can navigate this uncertain environment and protect their access to 340B pricing, and trends pertaining to audits of covered entities. Sponsored by PYA. Watch the conversation here.Essential Legal Updates, Now in AudioAHLA's popular Health Law Daily email newsletter is now a daily podcast, exclusively for AHLA Comprehensive members. Get all your health law news from the major media outlets on this podcast! To subscribe and add this private podcast feed to your podcast app, go to americanhealthlaw.org/dailypodcast.Stay At the Forefront of Health Legal EducationLearn more about AHLA and the educational resources available to the health law community at https://www.americanhealthlaw.org/.